November 21, 2026
$RichWire Markets and money, explained simply
LIVE
Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results Walmart Shares Waver Despite Topping Estimates as Growth Momentum Cools Bitcoin Slips Below Key Support Level as Bearish Technical Structure Takes Hold Bitcoin Tests Support Following Drop Below $60,000 Milestone Evaluating HF Sinclair and the Turning Oil Refining Cycle Bitcoin Technical Outlook Signals Persistent Bearish Structure Despite Short-Term Bounce Mapping Out a $500 Stake in Two Emerging Quantum Computing Enterprises Bitcoin Eyes Resistance Near $61,800 Following Support Bounce Analyst Suggests Taking Profits on Global X MSCI Colombia ETF Anthropic IPO Momentum Fades as Stock Slips Below Opening Levels Bitcoin Tests Critical Monthly Support Level as Traders Watch for Breakdown or Rebound Bitcoin Tests $58,000 Put Wall Following Market Flush CG Oncology Fair Value Revised Following Phase 3 Clinical Results

Comparing Two Major Biotech ETFs: FBT and IBB Strategy Differences

🧠 AI Analysis 2 min read 👁 4

A look at the structural differences between the First Trust NYSE Arca Biotechnology Index Fund and the iShares Biotechnology ETF shows distinct choices in cost and concentration for everyday investors.

Comparing Two Major Biotech ETFs: FBT and IBB Strategy Differences🧠AI Analysis

Photo: Motley Fool

Key points

  • FBT utilizes a concentrated, equal-weighted strategy with about 30 holdings.
  • IBB provides broader exposure with roughly 243 holdings and a market-cap weighting approach.
  • FBT delivered a 71% total return over five years compared to 40% for IBB.
  • IBB features a lower expense ratio of 0.44% versus 0.55% for FBT.

Contrasting Approaches in Healthcare Sector Funds

Navigating the healthcare sector through exchange-traded funds offers everyday market participants a way to bypass the severe single-stock risks inherent in medical research companies. Two prominent options—the First Trust NYSE Arca Biotechnology Index Fund (FBT) and the iShares Biotechnology ETF (IBB)—provide entirely different strategies for capturing growth in this space.

The First Trust product relies on a concentrated, equal-weighted model holding roughly 30 positions. Its top weightings include Genmab at 4.76%, Regeneron Pharmaceuticals at 4.00%, and ADMA Biologics at 3.99%. Conversely, the iShares fund tracks a much wider benchmark featuring 243 holdings, anchored by market-cap weighting. Its largest allocations consist of Gilead Sciences at 8.97%, Amgen at 8.31%, and Vertex Pharmaceuticals at 7.73%.

Performance Metrics and Expense Ratios

Historical returns diverge notably between the two vehicles. Over a five-year period, FBT generated a total return of 71%, translating to a compound annual growth rate of 11.3%. IBB posted a 40% total return over the same timeframe, with a 6.9% compound annual growth rate.

Management expenses also separate the choices. IBB charges a lower expense ratio of 0.44%, while FBT sets its fee at 0.55%. Regarding distributions, neither vehicle provides heavy cash flow, though IBB offers a minor dividend yield of 0.2%.

What to watch next: Monitor shifts in sector-wide valuations and expense ratio adjustments as broader macroeconomic volatility persists across healthcare equities.

Source Motley Fool — fool.com/coverage/etfs/2026/11/14/two-ways-to-play-biotech-fbt-s-re… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.